Updates from Johnson & Johnson
- Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential (Company update · November 16, 2026)
Johnson & Johnson reached an agreement to acquire Ollin Biosciences, adding the Phase 3 investigational bispecific antibody OLN324 to its portfolio. The treatment is designed for retinal vascular…